

Regular Meeting of the

Santa Clara County Health Authority Pharmacy and Therapeutics (P&T) Committee

Thursday, December 17, 2020, 6:00 - 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Via Teleconference

(408) 638-0968

Meeting ID: 932 7690 1993

Passcode: **SCFHP2020**

<https://zoom.us/j/93276901993>

AGENDA

- | | | | |
|--|-------------------------|--------------|----------------|
| 1. Roll Call / Establish Quorum | Dr. Lin | 6:00 | 5 min |
| 2. Public Comment
Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of the public comment period to 30 minutes. | Dr. Lin | 6:05 | 5 min |
| 3. Open Meeting Minutes
Review Santa Clara Family Health Plan (SCFHP) 3Q2020 P&T Open Session Minutes.
Possible Action: Approve SCFHP P&T Open Session Minutes | Dr. Lin | 6:10 | 2 min |
| 4. Standing Agenda Items | | | |
| a. Chief Medical Officer Health Plan Updates | Dr. Nakahira | 6:12 | 10 min |
| b. Medi-Cal Rx Update | Dr. Huynh | 6:22 | 5 min |
| c. Policy Review | | | |
| i. PH10 Cal MediConnect Part D Transition (2021)
Possible Action: Approve Pharmacy Policy PH10 Cal MediConnect Part D Transition | | | |
| 5. Plan/Global Medi-Cal Drug Use Review | | | |
| a. Drug Use Evaluation Update | Dr. Otomo
Dr. Nguyen | 6:27
6:30 | 3 min
5 min |
| b. 2019 4 th Quarter Report Emergency Supply Report | | | |
| c. Grievance & Appeals Pharmacy Report:
2020 1 st – 3 rd Quarter Reports | Ms. Luong | 6:35 | 5 min |
| Adjourn to Closed Session | | | |
| <i>Pursuant to Welfare and Institutions Code Section 14087.36 (w)</i> | | | |
| 6. Closed Meeting Minutes
Review SCFHP 3Q2020 P&T Closed Session Minutes.
Possible Action: Approve SCFHP P&T Closed Session Minutes | Dr. Lin | 6:40 | 2 min |

7. Metrics & Financial Updates			
a. Membership Report	Dr. Nakahira	6:42	3 min
b. Pharmacy Dashboard	Dr. Otomo	6:45	5 min
c. Pharmacy Member Portal Stats	Dr. Huynh	6:50	5 min
d. Drug Utilization & Spend	Dr. McCarty	6:55	5 min
8. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria	Dr. McCarty	7:00	5 min
a. Pharmacy Benefit Manager 3Q2020 P&T Minutes			
b. Pharmacy Benefit Manager 4Q2020 P&T Part D Actions Possible Action: Approve MedImpact Minutes & Actions			
c. 2021 Medical Benefit Drug Prior Authorization Grid Possible Action: Approve 2021 Medical Benefit Drug Prior Authorization Grid for Cal MediConnect	Dr. Otomo	7:05	5 min
9. Discussion and Recommendations for Changes to SCFHP's Medi-Cal Formulary & Prior Authorization Criteria	Dr. Nguyen	7:10	1 min
a. Old Business/Follow-Up			
i. Cefdinir Point-of-sale Message Update			
b. Formulary Modifications Possible Action: Approve Formulary Addition and Modification Recommendations	Dr. Otomo	7:11	5 min
c. Fee-for-Service Contract Drug List Comparability Possible Action: Approve CDL Comparability Formulary Recommendations	Dr. McCarty	7:16	5 min
d. 2021 Medical Benefit Drug Prior Authorization Grid Possible Action: Approve CDL Comparability Formulary Recommendations	Dr. Otomo	7:21	1 min
e. 2021 Medical Benefit Drug Prior Authorization Grid Possible Action: Approve 2021 Medical Benefit Drug Prior Authorization Grid for Medi-Cal	Dr. Nguyen	7:22	5 min
f. Prior Authorization Criteria			
i. <u>New or Revised Criteria</u>			
1. Protopic ointment			
2. Non-Formulary			
ii. <u>Annual Review</u>			
1. Norditropin Flexpro			
2. Zarxio			
Possible Action: Approve New/Revised and Annual Review Criteria			
10. New Drugs and Class Review			
a. Tardive Dyskinesia Review	Dr. Zhang	7:27	15 min
b. COVID-19 Vaccines			
c. Asthma Review	Dr. McCarty	7:42	15 min
d. Hereditary Angioedema (HAE) – Orladeyo			
e. New & Expanded Indications – Epidiolex, Spravato, Tremfya, and Simponi Aria Possible Action: Approve New Drug and Class Recommendations			
f. <u>Informational Only</u>			
i. Anemia Chronic Kidney Disease – Roxadustat			
ii. Systemic Lupus Erythematosus – Anifrolumab and Voclosporin			
iii. Acne – Winlevi			
iv. Duchenne Muscular Dystrophy – Viltepso			
v. Pain from Osteoarthritis – Tanezumab			
vi. Schizophrenia – Olanzapine/Samidorpham			

- vii. Fatty Acid Metabolism – Dojolvi
- viii. Attention Deficit Hyperactivity Disorder – Viloxazine
- ix. Overactive Bladder – Vibegron
- x. Heart Failure – Vericiguat
- xi. Chemo-induced Neutropenia – Rolontis
- xii. Hyperlipidemia – Inclisiran
- xiii. Ophthalmic NSAIDs
- xiv. New Derivatives, Formulations, and Combinations

Reconvene in Open Session

11. Discussion Items	Dr. McCarty	7:57	3 min
a. New and Generic Pipeline			
12. Adjournment	Dr. Lin	8:00	
Next meeting Thursday, March 18, 2021			

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The Committee may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Ave, San Jose, CA 95119.

This agenda and meeting documents are available at www.scfhp.com